KK
NBIX icon

KLP Kapitalforvaltning’s Neurocrine Biosciences NBIX Stock Holding History

KLP Kapitalforvaltning’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.44M Buy
38,200
+1,100
+3% +$163K 0.02% 466
2026
Q1 		$4.89M Hold
37,100
– – 0.02% 487
2025
Q4 		$5.26M Buy
37,100
+400
+1% +$57.9K 0.02% 483
2025
Q3 		$5.15M Hold
36,700
– – 0.02% 479
2025
Q2 		$4.61M Buy
36,700
+600
+2% +$68.8K 0.02% 489
2025
Q1 		$3.99M Buy
36,100
+1,300
+4% +$165K 0.02% 515
2024
Q4 		$4.75M Buy
+34,800
New +$4.3M 0.02% 498

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

KLP Kapitalforvaltning's NBIX Position: Q2 2026 in Review

KLP Kapitalforvaltning increased its Neurocrine Biosciences (NBIX) stake by 3% in Q2 2026, buying an estimated $163K and bringing the position to 38,200 shares worth $6.44M. The position accounts for 0.02% of the portfolio, ranked #466.

KLP Kapitalforvaltning first reported a position in NBIX in Q4 2024 and has held it in 7 quarters since. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • KLP Kapitalforvaltning held 38,200 shares of Neurocrine Biosciences worth $6.44M as of Q2 2026.
  • KLP Kapitalforvaltning bought 1,100 Neurocrine Biosciences shares in Q2 2026, an estimated $163K.
  • Neurocrine Biosciences made up 0.02% of KLP Kapitalforvaltning's portfolio in Q2 2026, its #466 holding.
  • KLP Kapitalforvaltning first reported a position in Neurocrine Biosciences in Q4 2024 and has held it in 7 quarters since.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on KLP Kapitalforvaltning's 13F filing for Q2 2026, filed 12 Aug 2026.